Abstract: The cytotoxic agents pemetrexed and docetaxel and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib are standard secondline therapies for nonsmall cell lung cancer. For patients without the EGFR mutation, more and more evidence has suggested the superiority of chemotherapy over targeted therapy. Adding targeted agents to standard secondline treatment is an trend of exploration, but without promising results nowadays. Crizotinib, targeting at anaplastic lymphoma kinase, has been shown excellent efficacy for secondline therapy in nonsmall cell lung cancer.